{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:05:39Z","timestamp":1771869939180,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T00:00:00Z","timestamp":1174521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non\u2010Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long\u2010term response, defined as a time to progression of 12 months or longer.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Long\u2010term responses were seen in 37% (78\/211) of patients. At a median follow\u2010up of 53.5 months (range, 12.7\u201388.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long\u2010term responders. The estimated overall survival at 5 years was 53% for all patients treated with <jats:sup>90<\/jats:sup>Y ibritumomab tiuxetan and 81% for long\u2010term responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>A single dose of <jats:sup>90<\/jats:sup>Y ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22617","type":"journal-article","created":{"date-parts":[[2007,3,22]],"date-time":"2007-03-22T20:03:18Z","timestamp":1174593798000},"page":"1804-1810","source":"Crossref","is-referenced-by-count":151,"title":["Long\u2010term responses in patients with recurring or refractory B\u2010cell non\u2010Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan"],"prefix":"10.1002","volume":"109","author":[{"given":"Thomas E.","family":"Witzig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Emmanouilides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Darif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Macklis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199909000-00009"},{"key":"e_1_2_5_4_2","first-page":"457","article-title":"Yttrium\u201090\u2010labeled anti\u2010CD20 monoclonal antibody therapy of recurrent B\u2010cell lymphoma","volume":"2","author":"Knox SJ","year":"1996","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.6.918"},{"key":"e_1_2_5_6_2","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non\u2010Hodgkin's lymphoma with (90)Y\u2010labeled anti\u2010CD20 monoclonal antibody","volume":"43","author":"Wagner HN","year":"2002","journal-title":"J Nucl Med."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3883"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.017"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4336"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.043"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2004.19.478"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.015"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.9217"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_5_18_2","first-page":"560","article-title":"Phase II trial of rituximab and short duration chemotherapy followed by 90Y\u2010ibritumomab tiuxetan as first\u2010line treatment for patients with follicular lymphoma: a Minnie Pearl Cancer Research Network phase II trial [abstract]","volume":"23","author":"Shipley DL","year":"2004","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500376076"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"720a","DOI":"10.1182\/blood.V104.11.2633.2633","article-title":"Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients with untreated low\u2010grade follicular lymphoma [abstract]","volume":"104","author":"Sweetenham JW","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21998"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.028"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.143"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.0892"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22617","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:19:39Z","timestamp":1760289579000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,18]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1002\/cncr.22617"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22617","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,18]]}}}